Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Several key aspects differentiate our library:


  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.

  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.

  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.

  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.


PARTNER
Receptor.AI
 
UPACC
Q9UBN7

UPID:
HDAC6_HUMAN

ALTERNATIVE NAMES:
Tubulin-lysine deacetylase HDAC6

ALTERNATIVE UPACC:
Q9UBN7; O94975; Q6NT75; Q7L3E5; Q96CY0

BACKGROUND:
The enzyme Histone deacetylase 6, or Tubulin-lysine deacetylase HDAC6, is integral to epigenetic repression through histone deacetylation. Beyond histones, HDAC6 targets tubulin and other proteins, influencing cell motility, autophagy, and protein degradation. Its role in the MTA1-mediated epigenetic regulation of ESR1 expression in breast cancer highlights its significance in cellular processes.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of Histone deacetylase 6 could open doors to potential therapeutic strategies. Its involvement in a specific genetic disorder characterized by skeletal dysplasia and neurodevelopmental anomalies underscores the therapeutic potential of HDAC6 modulation in treating complex diseases.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.